Andrew brings to JAZZ significant experience in venture capital, company building, technology development, and neurosurgery. He has served as founder, investor, director, and chairman of many successful companies.
Andrew has led numerous venture capital investments and has helped many early-stage companies become successful market leaders. Previously, he was a partner at Flare Capital Partners (formerly known as Foundation Medical Partners) and a principal at Canaan Partners. He was a founder (and invented the core technology) of Northstar Neuroscience, which went public in 2006 (NASDAQ: NSTR) and was subsequently acquired by St. Jude Medical (NYSE: STJ). He also served as chairman of IntElect Medical, which was acquired by Boston Scientific (NYSE: BSX).
Andrew's representative investments and board seats include Akili Interactive, Aira, BridgePoint Medical (acquired by Boston Scientific, NYSE: BSX), Explorys (acquired by IBM, NYSE: IBM), Embodied, Eyefluence (acquired by Google, NASDAQ: GOOGL), Freeletics, Functional Neuromodulation, Halo Neuroscience, Level EX, Pear Therapeutics, Pymetrics, SetPoint Medical, Thrive Global, Two Bit Circus, and Visiogen (acquired by Abbott, NYSE: ABT).
During more than a decade in the healthcare profession, he published more than 50 medical articles and was co-editor of a book about cerebrovascular surgery. His scientific work has been presented at many international conferences and he holds numerous patents for his inventions. As a board-certified neurosurgeon, he served as clinical assistant professor of neurosurgery at Yale School of Medicine and New York University School of Medicine. He has served on innovation advisory boards at Yale University, Cleveland Clinic, and Cornell University.
Andrew earned his MD from Weill Cornell Medicine and his MBA from the University of Pittsburgh after studying neuroscience at Cornell (AB) and Oxford University.